Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

about

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

Item

http://www.wikidata.org/entity/Q42371654

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@en

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@nl

type

Item

label

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@en

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@nl

prefLabel

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@en

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@nl

P1476

Targeted first-line therapies for advanced colorectal cancer: a Bayesian meta-analysis.

@en

P2093

Benjamin Haaland

http://www.w3.org/2001/XMLSchema#string

Geoffrey Ku

http://www.w3.org/2001/XMLSchema#string

Gilberto Lopes

http://www.w3.org/2001/XMLSchema#string

Hasan Masud

http://www.w3.org/2001/XMLSchema#string

Yassine Ridouane

http://www.w3.org/2001/XMLSchema#string

P2860

BRAF Mutation in Colorectal Cancer: An Update

Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

Cancer statistics, 2016

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors

P304

66458-66466

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.20185

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29029527

http://www.w3.org/2001/XMLSchema#string

P921

colorectal cancer

P932

5630427

http://www.w3.org/2001/XMLSchema#string